

# APPENDIX

## APPENDIX A

**Table A1. The list of included drugs.**

Category	Generic name
"4+7" List drugs	Atorvastatin, Amlodipine, Irbesartan, Irbesartan Hydrochlorothiazide, Fosinopril, Lisinopril, Losartan, Rosuvastatin, Enalapril, Escitalopram, Olanzapine, Risperidone, Paroxetine, Dexmedetomidine, Levetiracetam, Gefitinib, Pemetrexed Disodium, Imatinib, Entecavir, Tenofovir Disoproxil, Cefuroxime Axetil, Clopidogrel, Montmorillonite, Flurbiprofen, Montelukast
Alternate drugs	Adefovir Dipivoxil, Aripirazole, Allisartan Isoproxil, Aspirin, Amisulpride, Amlodipine Besylate and Atorvastatin Calcium, Amlodipine Besylate and Benazepril, Oxcarbazepine, Olmesartan Medoxomil, Olmesartan medoxomil and Hydrochlorothiazide, Benazepril and Hydrochlorothiazide, Levoamlodipine, Pemirolast potassium, Magnesium Valproate, Valproate Sodium, Dasatinib, Felodipine, Perphenazine, Fluvastatin Sodium, Haloperidol, Compound Captopril, Quetiapine, Osimertinib, Carbamazepine, Captopril, Candesartan Cilexetil and Hydrochlorothiazide, Candesartan Cilexetil, Lamivudine, Lamotrigine, Lisinopril and Hydrochlorothiazide, Ramipril, Lovastatin, Clozapine, Losartan and Hydrochlorothiazide, Afatinib, Fluvoxamine, Enalapril and Folic Acid, Midazolam, Nilotinib, Paliperidone, Perindopril, Perindopril and Indapamide, Pitavastatin Calcium, Pravastatin Sodium, Pranlukast hydrate, Albumini Tannas, Sulpiride, Diclofenao Sodium, Telbivudine, Ticagrelor, Telmisartan, Telmisartan and Hydrochlorothiazide, Ketorolac Tromethamine, Cefalexin, Cefprozil, Cefdinir, Cefaclor, Cefixime, Cefadroxil, Topiramate, Penfluridol, Cilostazol, Nifedipine, Valsartan and Amlodipine, Valsartan, Valsartan and Hydrochlorothiazide, Simvastatin, Xuezhikang, Icotinib, Bupropion, Benazepril, Duloxetine, Erlotinib, Fluoxetine, Tiapride, Loperamide, Chlorpromazine, Paroxetine, Ziprasidone, Trazodone, Tiolopidine, Sertraline, Venlafaxine, Berberine, Ezetimibe and Simvastatin, Zhibitai, Zhibikang, Parecoxib Sodium, Tenofovir Alafenamide, Perindopril arginine and amlodipine besylate, Vortioxetine, Piroxicam, Loxapine, Seratrodast, Trifluoperazine, Amlodipine folic acid, Olmesartan medoxomil and amlodipine

## APPENDIX B

**Table A2. The growth rate of volume, expenditures, and DDDc for the original and generic drugs in three types of medical institutions in the pilot cities.**

	Volume (%)			Expenditure (%)			DDDc (%)		
	Te	Se	Pr	Te	Se	Pr	Te	Se	Pr
<b>Bid-winning products</b>									
Original	129.56	110.81	42.67	6.55	113.25	-53.45	-53.59	1.16	-67.37
Generic	437.70	572.76	763.48	45.47	45.78	39.42	-72.95	-78.33	-83.85
Subtotal	422.07	548.51	691.27	40.59	48.27	32.90	-73.07	-77.14	-83.20
<b>Non-winning products</b>									
Original	-39.98	-45.23	-32.99	-47.90	-53.73	-43.68	-13.19	-15.51	-15.94
Generic	-74.94	-82.23	-83.27	-56.41	-73.52	-84.49	73.92	48.98	-7.28
Subtotal	-53.53	-69.58	-65.62	-51.22	-64.55	-61.26	4.98	16.54	12.66
<b>"4+7" List drugs</b>									
Original	-37.42	-41.41	-30.68	-46.08	-51.19	-43.86	-13.83	-16.70	-19.01
Generic	84.95	42.62	29.17	-28.54	-43.63	-53.31	-61.36	-60.47	-63.85
Subtotal	20.75	17.31	9.64	-38.01	-46.55	-48.57	-48.66	-54.44	-53.09
<b>Alternative drugs</b>									
Original	8.01	4.40	7.11	31.21	12.42	13.72	21.49	7.68	6.18
Generic	20.07	18.37	18.88	18.99	19.13	22.90	-0.91	0.65	3.38
Subtotal	12.50	12.09	13.93	26.35	16.43	19.10	12.31	3.88	4.53
<b>Overall policy-related drugs</b>									
Original	-11.43	-12.01	-7.71	-13.59	-21.62	-20.86	-2.44	-10.92	-14.24
Generic	54.66	30.84	23.94	-11.45	-15.45	-16.24	-42.75	-35.38	-32.42
Subtotal	16.40	14.46	11.98	-12.66	-17.88	-18.38	-24.96	-28.26	-27.11

Data are growth rate. Te refers to tertiary public hospital; Se refers to secondary public hospital; Pr refers to government-run primary medical institution.

**Table A3. The results of DID analysis for the change in purchase expenditures of original and generic drugs in different types of medical institutions.**

	Original drugs			Generic drugs		
	Tertiary	Secondary	Primary	Tertiary	Secondary	Primary
<b>Winning products</b>						
Constant, $\beta_0$	14.80***	3.57***	0.72***	70.10***	31.64***	5.47***
Time, $\beta_1$	8.18***	1.70**	0.35***	11.88*	7.61*	1.63**
Treat, $\beta_2$	-0.67	-2.05***	3.14***	15.92**	-3.13	45.97***
Treat*Group, $\beta_3$	-8.96**	-0.86	-2.32***	29.27**	6.06	21.78***
$R^2$	0.34	0.60	0.86	0.68	0.37	0.95
Relative change (%)	-60.54	-24.05	-323.99	41.76	19.14	398.06
<b>Non-winning products</b>						
Constant, $\beta_0$	210.27***	80.72***	12.90***	177.80***	95.19***	33.76***
Time, $\beta_1$	35.13**	36.29***	8.83***	27.27*	21.90*	9.69**
Treat, $\beta_2$	146.42***	-8.38	199.52***	52.04**	-7.87	129.59***
Treat*Group, $\beta_3$	-202.98***	-75.41***	-102.48***	-155.91***	-86.30***	-148.29***
$R^2$	0.78	0.76	0.97	0.68	0.75	0.92
Relative change (%)	-96.53	-93.43	-794.24	-87.69	-90.66	-439.21
<b>"4+7" List drugs</b>						
Constant, $\beta_0$	225.07***	84.28***	13.62***	247.90***	126.83***	39.23***
Time, $\beta_1$	43.31**	37.99***	9.18***	39.15*	29.51*	11.32**
Treat, $\beta_2$	145.75***	-10.43	202.66***	67.95**	-11.00	175.56***
Treat*Group, $\beta_3$	-211.93***	-76.27***	-104.80***	-126.63***	-80.25***	-126.51***
$R^2$	0.75	0.76	0.97	0.38	0.59	0.92
Relative change (%)	-94.16	-90.49	-769.49	-51.08	-63.27	-322.46
<b>Alternative drugs</b>						
Constant, $\beta_0$	131.78***	48.83***	13.62***	127.27***	91.56***	63.42***
Time, $\beta_1$	48.38***	10.22*	3.34**	20.38*	10.50	7.33
Treat, $\beta_2$	148.54***	16.34***	129.47***	62.53***	9.76	149.10***
Treat*Group, $\beta_3$	28.07	-4.22	16.18*	3.24	0.24	28.42*
$R^2$	0.90	0.46	0.97	0.59	0.12	0.93
Relative change (%)	21.30	-8.64	118.79	2.54	0.26	44.82
<b>Overall policy-related drugs</b>						
Constant, $\beta_0$	356.84***	133.11***	27.24***	375.17***	218.39***	102.65***
Time, $\beta_1$	91.69***	48.21***	12.52***	59.53*	40.00*	18.65*
Treat, $\beta_2$	294.29***	5.92	332.13***	130.48***	-1.24	324.66***
Treat*Group, $\beta_3$	-183.86***	-80.49***	-88.63***	-123.40**	-80.01**	-98.09***
$R^2$	0.78	0.50	0.97	0.36	0.26	0.92
Relative change (%)	-51.53	-60.47	-325.38	-32.89	-36.64	-95.55

\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . The data presented is the regression coefficient.

Tertiary means tertiary public hospital; Secondary means secondary public hospital; Primary means government-run primary medical institution.

**Table A4. The results of DID analysis for the change in the DDDc of original and generic drugs in different types of medical institutions.**


	Original drugs			Generic drugs		
	Tertiary	Secondary	Primary	Tertiary	Secondary	Primary
<b>Winning products</b>						
Constant, $\beta_0$	43.69***	8.40***	4.49***	7.82***	6.79***	4.68***
Time, $\beta_1$	1.58	0.86	0.11	-0.16	-0.28*	-0.17*
Treat, $\beta_2$	-21.79***	-2.71**	-0.35***	0.52***	0.27**	1.36***
Treat*Group, $\beta_3$	-13.06***	-1.74	-2.91***	-5.93***	-5.25***	-4.89***
$R^2$	0.920	0.512	0.988	0.992	0.991	0.990
Relative change (%)	-29.90	-20.72	-64.86	-75.77	-77.35	-104.45
<b>Non-winning products</b>						
Constant, $\beta_0$	10.49***	9.20***	8.18***	8.68***	4.91***	1.50***
Time, $\beta_1$	-0.70***	-0.34***	-0.67***	-0.27	0.22**	0.09***
Treat, $\beta_2$	-0.74***	-1.31***	-1.43***	1.14***	-0.003	1.27***
Treat*Group, $\beta_3$	-0.50***	-0.88***	-0.38	8.75***	2.65***	-0.34**
$R^2$	0.845	0.923	0.893	0.933	0.830	0.944
Relative change (%)	-4.77	-9.57	-4.67	100.77	54.01	-22.93
<b>"4+7" List drugs</b>						
Constant, $\beta_0$	11.03***	9.16***	7.85***	8.42***	5.27***	1.66***
Time, $\beta_1$	-0.54***	-0.29**	-0.56***	-0.24	0.15*	0.09***
Treat, $\beta_2$	-1.06***	-1.32***	-1.18***	0.95***	0.03	1.53***
Treat*Group, $\beta_3$	-0.78***	-1.05***	-0.69***	-5.48***	-3.34***	-2.12***
$R^2$	0.906	0.935	0.894	0.974	0.984	0.982
Relative change (%)	-7.07	-11.40	-8.83	-65.05	-63.42	-127.88
<b>Alternative drugs</b>						
Constant, $\beta_0$	4.35***	2.77***	2.13***	4.04***	2.64***	1.16***
Time, $\beta_1$	0.93***	0.27***	0.28***	0.18**	-0.01	0.01
Treat, $\beta_2$	1.21***	1.08***	0.76***	2.11***	2.07***	1.82***
Treat*Group, $\beta_3$	0.15	-0.02	-0.12	-0.29*	-0.05	0.06*
$R^2$	0.874	0.954	0.925	0.969	0.988	0.997
Relative change (%)	3.43	-0.83	-5.58	-7.16	-2.01	4.75
<b>Overall policy-related drugs</b>						
Constant, $\beta_0$	7.03***	4.96***	3.36***	6.16***	3.71***	1.31***
Time, $\beta_1$	0.48***	0.50***	0.55***	0.04	0.10*	0.05**
Treat, $\beta_2$	0.39***	0.32***	1.03***	1.67***	1.30***	1.77***
Treat*Group, $\beta_3$	-0.66***	-1.10***	-1.19***	-3.36***	-1.88***	-1.04***
$R^2$	0.450	0.743	0.815	0.968	0.980	0.994
Relative change (%)	-9.37	-22.16	-35.50	-54.48	-50.48	-79.69










\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . The data presented is the regression coefficient.

Tertiary means tertiary public hospital; Secondary means secondary public hospital; Primary means government-run primary medical institution.


## APPENDIX C










**Figure A1. Purchase volume of original and generic drugs in the pilot group vs control group in the months prior and after the “4+7” policy implementation.**





**Figure A2. Purchase Expenditures of original and generic drugs in the pilot group vs control group in the months prior and after the “4+7” policy implementation.**







**Figure A3. The DDDc of original and generic drugs in the pilot group vs control group in the months prior and after the “4+7” policy implementation.**

